Back to results
US 6,297,223 B1Granted
Uracil reductase inactivatores
AssigneeGlaxo Wellcome Inc.
InventorsThomas Spector, David J. T. Porter, Saad G. Rahim
Life of this patent
Estimating the term…
Abstract
Uracil reductase inactivators, notably a 5-substituted uracil or 5,6-dihydro-5-substituted uracil, potentiate 5-fluorouracil and find use particularly in the treatment of cancer. The 5-substituent is selected from bromo, iodo, cyano, halo-substituted C1-4 alkyl, C2-6 alkenyl, 1-halo-C2-6 alkenyl and halo-substituted C2-6 aklynyl.
Claims10
A method of enhancing activity of 5-fluorouracil in a mammal, comprising administering to the mammal
- (i) an effective amount of a 5-substituted- or 5,6-dihydro-5-substituted-uracil derivative, wherein the substituent at the 5 position is halo substituted C1-4 alkyl, C2-6 alkenyl, 1-halo- C2-6 alkenyl, or C2-6 alkynyl, or a prodrug thereof;
- in conjunction with
- (ii) 5-fluorouracil or pro-drug thereof.
Dependencies are inferred from the claim text.